Vitae Pharmaceuticals (VTAE) Is Alzheimer's Disease Preventable?, KLA-Tencor (KLAC) Leveraged Recapitalization Strategy |
Posted: October 24, 2014 |
Vitae Pharmaceuticals, Inc. (VTAE) Alzheimer's disease is a progressive, degenerative disorder that attacks the brain's nerve cells, or neurons, resulting in loss of memory, thinking and language skills, and behavioral changes. Symptoms usually develop slowly and get worse over time, becoming severe enough to interfere with daily tasks. Alzheimer's disease is the most common cause of dementia, or loss of intellectual function, among people aged 65 and older. Research suggests that certain lifestyle factors, such as a nutritious diet, exercise, social engagement, and mentally stimulating pursuits, might help to reduce the risk of cognitive decline and Alzheimer's disease. According to the Centers for Disease Control, Alzheimer's disease was the 6th leading cause of death in the United States in 2013. In addition, as of 2013, an estimated 5.1 million Americans had Alzheimer's disease, nearly all of whom are aged 65 or older, and approximately 200,000 individuals under age 65 have early onset of Alzheimer's disease. Although current Alzheimer's treatments cannot stop Alzheimer's from progressing, they can temporarily slow the worsening of dementia symptoms and improve quality of life for those with Alzheimer's and their caregivers. Today, there is a worldwide effort under way to find better ways to treat the disease, delay its onset, and prevent it from developing VTAE reported positive top-line results from clinical trials in treatment and prevention of Alzheimer's disease as part of the collaboration with Boehringer Ingelheim. The two Phase 1 clinical trials of BI1181181/VTP-37948, an orally active beta secretase (BACE) inhibitor discovered by VTAE and developed by Boehringer Ingelheim, are randomized, placebo-controlled single dose studies (a single rising dose and a proof of mechanism study). In the study, BI1181181/VTP-37948 was safe and generally well-tolerated across all dose levels tested. Also, the results indicated a half-life of between 16 and 19 hours, supporting a once-daily dosing profile. Plaques of amyloid beta in the brain are one of the primary indicators of Alzheimer's disease. In this trial, BI1181181/VTP-37948 demonstrated the ability to lower amyloid beta levels in cerebral spinal fluid by more than 80%. VTAE is a clinical-stage biotechnology company focused on discovering and developing novel, small molecule drugs for diseases in which there are significant unmet medical needs. VTAE is developing a robust and growing portfolio of novel product candidates generated by Contour(R), its proprietary structure- based drug discovery platform. More about Vitae Pharmaceuticals, Inc. (VTAE) at www.vitaepharma.com. ** Crown Equity Holdings Inc. (CRWE) CRWE provides marketing solutions that boost customer awareness and merchant visibility on the Internet. CRWE is currently developing its CRWE Network ( www.CRWE-PR.com ), a growing network of website communities. The CRWE Network has reached the 1440th community website in the U.S., associated with 3320 ZIP Codes, and includes coverage of the greater state of California, Northern and Southern Nevada, New York State, Wellington in Florida, Hattiesburg in Mississippi and 10 provinces in Canada. CRWE has included the City of North Tonawanda, NY ( www.northtonawanda.ny.crwe-pr.com ) to the CRWE Network. Situated between western New York’s major metropolitan centers, Buffalo and Niagara Falls, North Tonawanda offers a great diversity of outdoor recreational, cultural and entertainment opportunities. And as an emerging gateway for international cargo, Tonawanda’s natural resources, location and infrastructure create the perfect catalyst for economic and industrial growth. With an estimated population in 2013 (U.S. Census Bureau) of approximately 31,097, North Tonawanda, NY represents an important marketplace for the CRWE Network, which business model is based on selling advertising to businesses targeting both locally and nationally Online video is quickly becoming one of the most popular forms of content on the Internet. 51.9% of marketing professionals worldwide cite video as the type of content with the best ROI (eMarketer). Globally, according to Cisco Visual Networking Index, IP video traffic will be 79% of all consumer Internet traffic in 2018. Strategic plans are being developed for CRWE’s division CRWE Tube ( www.crwetube.com ) to improve the potential future growth for the company. The CRWE-PR Finance website ( www.finance.crwe-pr.com ) allows CRWE the instant distribution of information to the entire CRWE Network. More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com ** KLA-Tencor Corp. (KLAC) KLAC announced a plan to significantly accelerate its strategy to drive stockholder returns. As part of KLAC's ongoing commitment to deliver stockholder value, the Board of Directors has authorized the financing of a leveraged recapitalization, which would feature a special cash dividend of $16.50 per share. Subject to the close of necessary financing, the Board of Directors currently intends to declare and pay the special cash dividend before December 31, 2014. The special cash dividend would be in addition to KLAC's regular $0.50 per share quarterly cash dividend. KLAC's regular $0.50 per share quarterly cash dividend is expected to be declared and paid following the Company's regularly scheduled Board of Directors meeting in November 2014. In connection with the leveraged recapitalization, KLAC's Board of Directors has approved an increase to the Company's stock repurchase program for up to 3.6 million additional shares of KLAC's common stock. For its first quarter of fiscal year 2015, KLAC posted GAAP net income of $72 million and GAAP earnings per diluted share of $0.43 on revenues of $643 million. KLAC, a leading provider of process control and yield management solutions, partners with customers around the world to develop state-of-the-art inspection and metrology technologies. These technologies serve the semiconductor, LED and other related nanoelectronics industries. More about KLA-Tencor Corp. (KLAC) at www.kla-tencor.com. ** Read Full Disclaimer at www.finance.crwe-pr.com/disclaimer
|
||||||||||||||||||||||||||||||||||||||||||
|